Target intelligence / Profile preview

LARGE xylosyl- and glucuronyltransferase 1 (LARGE1)

Target
LARGE1
Molecular classification
Enzyme, Glycosyltransferase, Golgi protein
01

Overview

LARGE xylosyl- and glucuronyltransferase 1 (LARGE1) is a bifunctional glycosyltransferase enzyme localized in the Golgi apparatus, primarily responsible for synthesizing matriglycan polymers by adding alternating xylose and glucuronic acid sugars to specific proteins, most notably α-dystroglycan. These modifications are essential for proper structural and signaling functions at the interface between the extracellular matrix and the cytoskeleton, especially in skeletal muscle and neural tissue. Mutations or loss of function in LARGE1 disrupt α-dystroglycan glycosylation, weakening the connection between the cell and its extracellular environment and resulting in a spectrum of congenital muscular dystrophies and neurodevelopmental disorders. The enzyme has been implicated in tumor progression and is a potential, albeit not yet pharmaceutically targeted, therapeutic enzyme for conditions related to dystroglycan hypoglycosylation.

Other names
LARGE glycosyltransferase 1Glycosyltransferase-like protein LARGE1Acetylglucosaminyltransferase-like 1AAlpha-1,3-xylosyltransferase LARGE1Beta-1,3-glucuronyltransferase LARGE1KIAA0609Glycosyltransferase-like proteinMDC1DMDDGA6MDDGB6xylosyl- and glucuronyltransferase LARGE1acetylglucosaminyltransferase-like proteinglycosyltransferase-like protein LARGE1
02

Biological functions

Protein glycosylation (specifically, addition of repeating disaccharide units of xylose and glucuronic acid to α-dystroglycan)Extracellular matrix organizationCell-matrix adhesionRegulation of cell–cell interactionsNeural development (neuronal migration)Muscle function and maintenance
03

Disease associations

Congenital muscular dystrophies (especially dystroglycanopathies, e.g., MDC1D, Fukuyama type, Walker-Warburg syndrome)Congenital disorders of glycosylation (CDG)Neurodevelopmental disordersCancer (roles in tumorigenesis, metastasis)
04

Safety considerations

Potential for affecting multiple tissues (brain, muscle, heart) due to its systemic and developmental rolesRisk of muscle degeneration and neuronal migration defects if inhibited or mutated
05

Biomarkers

Abnormal glycosylation of α-dystroglycan (used for diagnosis of α-dystroglycanopathies)Reduced matriglycan synthesis

Beyond the preview

Go deeper on LARGE xylosyl- and glucuronyltransferase 1 (LARGE1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LARGE xylosyl- and glucuronyltransferase 1 (LARGE1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call